Unilabs and Ibex are teaming up to make cancer diagnosis more accurate, timely, and targeted.
Per the new deal, Unilabs will deploy Ibex’s AI-powered, multi-tissue Galen platform in pathology labs across Europe. Backed by advanced machine learning algorithms, the platform evaluates tissue biopsies in real time to offer valuable insights on tumor grading and size.
Other notable features of the Galen include worklists for case prioritization and cancer heatmaps for increased diagnostic accuracy.
"This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes," said Dr. Christian Rebhan, chief medical and operations officer at Unilabs.
Rebhan continued, "When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs' pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe."
Galen by Ibex is CE-marked for breast and prostate cancer detection. Unilabs will roll out Ibex's platform to 16 countries, starting with Sweden.
DevOps: A view from the enterprise
What's driving DevOps, the impact of value stream management, and more
"Ibex is transforming cancer diagnosis with innovative AI solutions across the diagnostic pathway," said Joseph Mossel, chief executive officer (CEO) and co-founder of Ibex Medical Analytics.
"We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis. This cooperation follows a thorough evaluation of our technology at Unilabs, and demonstrates the robustness and utility of our platform for everyday clinical practice."
